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Abstract: Biocompatibility improvements for blood contacting materials are of increasing 
interest for implanted devices and interventional tools. The current study focuses on 
inorganic (titanium, titanium nitride, titanium oxide) as well as diamond-like carbon (DLC) 
coating materials on polymer surfaces (thermoplastic polyurethane), deposited by 
magnetron sputtering und pulsed laser deposition at room temperature. DLC was used pure 
(a-C:H) as well as doped with silicon, titanium, and nitrogen + titanium (a-C:H:Si,   
a-C:H:Ti, a-C:H:N:Ti). In-vitro testing of the hemocompatibility requires mandatory 
dynamic test conditions to simulate in-vivo conditions, e.g., realized by a cone-and-plate 
analyzer. In such tests, titanium- and nitrogen-doped DLC and titanium nitride were found 
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to be optimally anti-thrombotic and better than state-of-the-art polyurethane polymers.   
This is mainly due to the low tendency to platelet microparticle formation, a high content 
of remaining platelets in the whole blood after testing and low concentration of platelet 
activation and aggregation markers. Comparing this result to shear-flow induced cell 
motility tests with e.g., Dictostelium discoideum cell model organism reveals similar 
tendencies for the investigated materials. 
Keywords:  inorganic thin film materials; diamond-like carbon; dynamic blood   
testing; blood 
 
1. Introduction 
Biomedical devices (artificial hearts, lungs, kidneys, etc.) and interventional tools (stents, 
guidewires, catheters, etc.) play a major role in treating disease and organ insufficiency in the aging 
population. However, human immune reactions to implanted biomaterials work against the intention to 
heal disease, and may even cause serious harm or death [1]. When a biomaterial is implanted in a 
blood vessel in the human body, water and protein adsorption to surfaces immediately occurs. Then, 
cells such as leucocytes and platelets contact biomaterial surfaces and are activated due to stimulation 
by cytokines and growth factors [2,3]. Common failures of biomaterials arise from thrombogenesis. 
This thrombus formation occurs normally only at the site of vascular injury and involves platelet 
adhesion followed by the activation of blood clotting cascade and formation of fibrin clot. Thus, a 
significant factor determining hemocompatibility is the platelets’ response to the surface of a 
biomaterial, as indicated by their morphological changes [4,5]. Although blood platelets are a major 
morphotic component of thrombus, other cells, like erythrocytes and leukocytes, can also accumulate 
at the site of fibrin deposition. Activated leukocytes easily adhere to the surface of endothelial cells, 
and migrate out of the bloodstream into surrounding tissues. 
Biomaterial improvements are generally achieved by surface modifications. Surface modification 
techniques either change the existing surface or apply an additional layer on the surface. Plasma 
techniques offer a great variety for such changes on metal, ceramics and polymer surfaces. Plasma 
sterilizes and cleans surfaces (from manufacturing residues), but also promotes adhesion for subsequent 
deposits (further coatings, proteins, cells) by chemical, mechanical and topographical changes. Basic 
processes are ablation to remove the outermost layer, implantation of oxygen or nitrogen atoms, 
radical formation on the surface, and deposition of polymers, metals or ceramic materials of generally 
a few nanometers to ~50 micrometers thickness. Many of the plasma-based deposition processes 
(physical and plasma-activated chemical vapor deposition) require elevated temperatures (>150–200 °C) 
to reach the desired properties of the surfaces. However, a lot of medically applied polymers can 
withstand only temperatures of up to 70–100 °C. Thus, there is increasing focus to develop low 
temperature physical and chemical vapor deposition techniques for deposition of e.g., inorganic 
coatings and diamond-like carbon (DLC). 
Several studies reported about the biocompatibility of DLC coatings, like amorphous hydrogenated 
carbon (a-C:H) [6–10]. DLC generally consists of an amorphous matrix of sp2 and sp3 bonded carbon J. Funct. Biomater. 2012, 3  285 
 
 
atoms. Carbon-based thin films with an increased fraction of sp3 bonds are known to possess   
high mechanical hardness, low surface roughness, chemical inertness, and exhibit good blood 
compatibility [11,12]. In addition, carbon layers developed onto polytetrafluoroethylene were observed 
to drastically increase adhesion and proliferation of human endothelial cells, which is beneficial for 
stent applications [13]. Further attempts to improve the anti-thrombus and physical properties have 
involved adding elements such as fluorine [1,14,15], silicon [16], phosphorus [17] and boron [18] to 
DLC. Fluorinated DLC films have performed particularly well in both blood adaptability and in vivo 
biocompatibility [15]. There are thought to be numerous mechanisms that prevent the adhesion and 
activation of platelets on DLC or doped-DLC, mediated proteins, chemical properties of the surfaces, 
wettability and surface structures. In contrast, increased binding of platelets was found for titanium and 
titanium nitride (TiN) surfaces and the state of platelet activation seemed to be more pronounced [19]. 
Comparative studies have also reported that DLC was found to be more hemocompatible than other 
biomaterials such as Ti, TiN, titanium carbide and carbonitrides [20–23]—however, with some 
controversial results. 
The aim of this work is improving biomaterial surfaces by various metal and DLC based coatings, 
deposited at room temperature by magnetron sputtering and pulsed laser deposition (PLD) on 
thermoplastic polyurethane (PU) surfaces in order to achieve low platelet activation and aggregation. 
2. Results and Discussion 
The platelet’s main role in hemostasis is to preserve the integrity of the vascular wall through 
formation of a platelet plug. Testing the platelet function in-vitro in proximity to biomaterial surfaces 
requires dynamic testing to simulate the conditions resulting in platelet adhesion and aggregation, the 
most dangerous situation in blood contact. Platelets (PLT) respond to minimal stimulation—both 
during the transport in the flowing blood, which depends on the flow conditions, and the reaction with 
the surface, which depends on the nature of the surface and the adsorbed proteins [24]. 
PLT adhesion on (damaged) vessel walls occurs in-vivo under high shear forces, which are realized 
in this study in-vitro by the cone-and-plate (let) analyzer (CPA) setup. Primary PLT adhesion as the 
first step of primary hemostasis is characterized by initially reversible adhesion of still resting PLTs on 
the damaged vessel wall (or the biomaterial) [25], but can result in PLT activation (secondary   
adhesion) [26]. Activation occurs if adhering PLTs detect shear stresses that are too high   
(shear-induced pathway [27], or if they contact any thrombogenic surface such as injured endothelium, 
subendothelium and artificial surfaces (biomaterial induced PLT activation [28]). 
PLT adhesion, activation and finally aggregation are regulated by glycoproteins (GP) at the PLT 
membrane, which recognize specific structural components of the extracellular matrix in the 
subendothelium and media. The GPs IIb-IIIa complexes play central roles and have the highest density 
on PLTs among the different PLT adhesion receptors (see e.g., [24]): In the shear-induced adhesion 
pathway [27], first the binding of von Willebrand factor (vWF) to the GP Ib receptor, then the expression 
of activated GP IIb-IIIa and release of PLT vWF, and finally, vWF binding to GP IIb-IIIa leads to 
irreversible adhesion. On resting PLTs, GP IIb-IIIa is in an inactive form and has a low-affinity binding 
site for adsorbed fibrinogen [29] and soluble plasma fibrinogen cannot bind to the PLT surface. Binding 
sites for fibrinogen in the region of GP IIb-IIIa only become accessible after PLT activation and J. Funct. Biomater. 2012, 3  286 
 
 
conformational change. Thus, measuring PLTs with active GP IIb-IIIa complex gives detailed 
information about PLT function and fibrinogen binding: In our study (Figure 1d), GP IIb-IIIa was found 
to be evident in low concentrations in flow cytometry of the tested liquid for PU, a-C:H, a-C:H:Ti, TiN, 
and a-C:H:N:Ti, while a:C:H:Si, Ti, and TiOx show significantly higher values. However, these results 
have to be discussed, including the adhering PLTs and PLT aggregates found in confocal microscopy: 
Such mechanisms occur for a-C:H and Ti, while contrariwise, no adhesion was found for all other 
analyzed biomaterials. This finding will become important in the further discussion as well. 
Figure 1. Plots ranking hemobiocompatibility of tested materials in dependency on the 
percentage of PLTs remaining after dynamic shear stress testing in the CPA device:   
(a) percentage of PLT aggregates; (b) percentage of P-selectin positive PLT; (c) percentage 
of PLT-monocyte aggregates; (d) percentage of GP IIb/IIIa positive PLTs. 
 
While the initial binding of fibrinogen to GP IIb-IIIa is a reversible process (primary aggregation), 
it is followed seconds to minutes later by an irreversible stabilization of the fibrinogen linkage to the 
GP IIb-IIIa complex (secondary aggregation) [30]. In our study, CPA testing time was 5 min and about 
a similar amount of time was necessary subsequently for flow cytometry analyzing. Thus, we think 
that all GP IIb-IIIa positive PLTs are linked irreversibly to fibrinogen and have undergone the 
rearrangement of the PLT membrane and a drastic shape change [28]. Based on theories [31], the 
multivalent adhesion molecule fibrinogen possesses specific binding sites in the α- and γ-chains, which J. Funct. Biomater. 2012, 3  287 
 
 
can bind to two GP IIb-IIIa molecules, whereby each is on a different PLT. Thus, PLT-PLT 
microaggregates are formed during aggregation. These microaggregates were analyzed for the 
biomaterial coatings and are presented in Figure 1a: On all non-PLT adhesive surfaces rather similar 
concentrations of PLT-PLT microaggregates are evident, only TiN has a significantly lower tendency 
to aggregation. Quite similar results were found for bigger aggregates >2–3 PLTs. The PLT adhesive 
surfaces Ti and a-C:H resulted in lower aggregate concentrations in the tested liquid. 
PLT aggregation is accompanied by the release of Ca
2+ and fibrinogen into the surrounding, stored 
in high concentrations in resting PLT granules. Two mechanisms of secretion (or degranulation) are 
known: (1) The granules can give up their contents to the extracellular space on coalescence with the 
open canicular system. (2) Direct secretion to the surrounding space can occur through coalescence of 
the granule’s membrane with the plasma membrane (exocytosis) [32]. Both granule secretion 
processes reinforce and boost the activation/agglomeration process, because the binding via the GP 
IIb-IIIa complex is strongly dependent on (high) Ca
2+ concentrations. Reasonably, further circulating 
PLTs are recruited, and the PLT thrombus is consolidated by promoting the formation of fibrin [32].  
Secretion of the α granules also results in the release of the glycoprotein P selectin from these 
granules, which is translocated to the membrane surface and to plasma [33]. P-selectin plays an 
important role in mediating adhesion of activated PLTs to neutrophils, monocytes and a subset of 
lymphocytes [34,35] and triggers inflammatory reactions in leukocytes. Flow cytometry analyses of  
P-selectin positive PLTs (Figure 1b) show no significant differences for all investigated materials 
(except for the PLT adherent Ti and a-C:H). Evaluation of the PLT-monocyte aggregates (Figure 1c) 
and PLT-neutrophile showed quite similar results for all materials as well, except for a-C:H:N:Ti and  
a-C:H:Si, being significantly higher and lower, respectively. Generally, the PLT-leukocyte aggregates 
are based on fibrinogen cross-linking via GP IIb-IIIa and Mac-1 on leukocyte (monocytes or neutrophils). 
PLT activation and aggregation leads to a high consumption of PLTs, removing them from 
circulation. This is characterized by high PLT turnover rather than their adherence and by the formation 
of microemboli rather than occlusive thrombi formation. Following contact with the biomaterial (or the 
layer of adsorbed proteins on the artificial surface), PLTs will either adhere—as found for Ti and  
a-C:H—or “bounce off”, found for the other coatings and uncoated PU [36–38]. Considering this 
parameter in the ranking of the investigated biomaterial coatings leads to the abscissae in all diagrams 
in Figures 1 and 2. a-C:H:Si as well as a-C:H:Ti were found to be best materials regarding preventing 
PLT consumption. Overall, using this parameter for lining-up biomaterials in the diagrams defines the 
lower right part as most suitable for diminished interaction to PLTs and the upper left part as highly 
thrombogenic. Furthermore, it is not as simple to define a non-thrombogenic surface alone as   
“non-supporting PLT adhesion”. Moreover, this parameter of PLT consumption was proposed to be 
the most important in PLT hemocompatibility testing [39].  
Finally, PLT activation can result in the formation of PLT-rich microparticles (PMP) [33,40,41], 
which are particularly rich in factor Va, PLT factor 3 and phospholipid-like procoagulant activity 
(phosphatidylserine) [42,43]. Microparticle formation reflects fragmentation of PLTs and release of cell 
membrane vesicles during exocytosis and impose a thrombotic burden to circulating blood [39–42]. 
Recently, this was found to correlate with atherosclerosis and the risk for major adverse cardiovascular 
events, such as heart infarct or stroke [43,44]. Their detailed physiological role remains unclear, but  
in-vitro results have shown that they can bind and adhere to fibrinogen and fibrin, and coaggregate J. Funct. Biomater. 2012, 3  288 
 
 
with PLTs [45,46]. Microparticles of thrombogenic activity were generally found to be increasing for 
decreasing PLT consumption. The best material in our studies regarding this aspect is a-C:H:N:Ti 
(Figure 2). 
Figure 2. Concentration of microparticles with thrombogenic activity in dependency on the 
percentage of PLTs remained after dynamic shear stress testing. 
 
Finally, ranking of the investigated biomaterials coatings, concerning all the above-mentioned 
aspects, leads to a-C:H:N:Ti and TiN to be optimally applicable and much better than state-of-the-art 
PU, possessing the least thrombogenic surface and inducing least impact to the test blood. a-C:H:Si is 
a further candidate, however struggles with to high GP IIb-IIIa activation. High surface adhesion of 
PLTs, apparently improving the flow cytometry analysis of the liquid at first glance, and worst 
behavior regarding PLT consumption were found for Ti, a-C:H (and TiOx).  
Similar results of cell adhesion on these biomaterials were achieved by studying shear-flow-induced 
cell motility (SFICM) based on the setup used by Lauffenburger et al. [47–50] with Dictyostelium 
discoideum Ax-2 cell line model organisms (in their vegetative phase) (for details compare to [50]). 
The setup is based on a lower horizontal disc (titanium or silicon with the different biomaterial 
coatings) and a second, upper disc (stainless steel) with a small centre hole in 0.1 mm distance (see for 
details [51]). D. discoideum cells are initially placed on the lower discs and washed away during 
testing if the exerted shear forces by Sörensen phosphate buffer introduced by the centre hole are too 
high. Such conditions are found close to the centre hole—the critical shear stress is defined for the 
position, where 50% of cells are detached under time-dependent equilibrium conditions. In this study, 
extremely high hydrodynamic stress (>60 Pa) is required to detach D. discoideum cells from a-C:H 
surfaces independently on the substrate. Slightly lower threshold stress was found for Ti (~40 Pa). 
Lowest adhesion is found for TiN and a-C:H:N:Ti (10–20 Pa) [51]. Although D. discoideum cells and 
PLTs are limitedly comparable, the similarity in results is astonishing—even the stress level for 
attachment is comparable: In the CPA device we used bet 10–15 Pa shear stress for PLT function 
testing (in-vivo in healthy vessels 1–2 Pa and increase to 10–15 Pa during vessel injury). J. Funct. Biomater. 2012, 3  289 
 
 
The origin of the differences in the biomaterial behavior seems to be the protein adsorption: During 
first contact with blood, a biomaterial surface is mainly coated with albumin, immunoglobulins and 
fibrinogen from plasma. Adhesion of PLTs to fibrinogen onto these surfaces is not as irreversible as to 
collagen coated with vWF multimers of a damaged blood vessel [52]. Activation by adenosine 
diphosphate (ADP) is required for resting PLTs to efficiently adhere to fibrinogen [53]. Furthermore, 
fibrinogen appears to mediate PLT aggregation efficiently only under low shear stress conditions   
(1–3 Pa), but not at high shear stress (>5 Pa) [54], which occur e.g., in damaged vessels and were used 
in our tests. Our studies of bovine serum albumin (BSA) and fibronectin (Fn) adsorption, presented in 
detail elsewhere, revealed lower BSA adsorption for Ti and TiOx. However, it is even much higher 
than found for PU. All other coatings have quite similar adsorption of BSA. Fn adsorption is also 
similar for all coatings, but about 5 times higher than for uncoated PU. Such behavior can be the 
explanation for worse PLT function by high PLT consumption and high concentration of GP IIb-IIIa 
positive PLTs of these materials. Surface charge could be another influence on the protein adsorption 
properties, which will be applied in future research.  
3. Experimental Section  
3.1. Substrate Materials, Surface Modification and Deposited Films 
In the current work, we used Pulsed Laser Deposition (PLD) for ablating the metal target surface by 
a high power, pulsed laser beam (Nd:YAG laser, Powerlite/Continuum Inc/Santa Clara/CA/US,   
1064 nm wavelength, ~10 ns pulse duration, 50 Hz pulsing rate) [55,56] after evacuation of the 
chamber to pressures <2 × 10
3 Pa and a pretreatment (activation) step by a linear anode layer ion beam 
(Veeco Inc./Fort Collins/CO/US) in argon-oxygen plasma [57]. Additionally, coatings were deposited 
after similar evacuation and pretreatment by magnetron sputtering with argon sputter gas and direct 
current (DC), high frequency (HF = pulsed DC) and radio frequency (RF) power. The substrate 
temperature in the industrially-scaled, large-area and high rate PLD and magnetron sputtering 
equipment (Pfeiffer Vakuum/Vienna/Austria, Leybold Vakuum/Cologne/Germany) was kept at room 
temperature (max. 25 °C). Several different film materials were deposited by these techniques:   
pure titanium (Ti), titanium nitride (TiN), titanium oxide (TiOx), a-C:H, silicon, and titanium doped  
a-C:H (a-C:H:Si, a-C:H:Ti) as well as titanium plus nitrogen doped a-C:H (a-C:H:N:Ti). Materials  
and deposition techniques are listed in Table 1. Gases were supplied by Linde Gas GmbH   
(Stadl-Paura/Austria) in 99.996% purity  for Ar, N2 and O2 and 99.5% purity for acetylene (C2H2).  
Table 1. Film materials and deposition parameters. 
Material  Deposition 
technique  Target material  Target manufacturer Process  gases 
Ti  Sputter (DC)  Ti (grade 2)  Eurotitan GmbH, 
Solingen, Germany 
Ar 
TiN  PLD  Ti (grade 2)  N2, Ar 
TiOx  Sputter (HF)  Ti (grade 2)  O2, Ar 
a-C:H Sputter  (HF)  Electrocarbon graphite 
(99.7% carbon) 
Hoffmann & Co., 
Steeg, Austria  C2H2, Ar 
Si:a-C:H  Sputter (RF)  Ti (grade 2)  Eurotitan GmbH, 
Solingen, Germany 
C2H2, Ar 
Ti:a-C:H  Sputter (HF)  Ti (grade 2)  C2H2, Ar 
Ti:a-C:H:N  PLD  Ti (grade 2)  C2H2, N2, Ar J. Funct. Biomater. 2012, 3  290 
 
 
The deposition resulted in 20 nm thick films on 2 mm thick thermoplastic polyurethane substrates 
(PU, Elasthane 55D, DSM PTG/Berkeley/CA/US, thermal stability ~65°), kindly provided by the 
Foundation for Cardiac Surgery Development/Zabze/Poland. Additionally, 300 nm thick films were 
grown on silicon wafers (B-doped, Wacker Chemie AG/München/Germany) and Grade-2 titanium 
(Eurotitan GmbH/Solingen/Germany) substrates. Silicon wafers had 2" diameter and 500 µm thickness, 
titanium discs 2 mm thickness. Ti and stoichiometric TiN films were found to be nanocrystalline, all 
other films amorphous (see cross section in Figure 3b) with strong binding to the PU substrate (no 
delaminations). Si:a-C:H films contain 8.4% Si, Ti:a-C:H films ~10% Ti. Ti:a-C:H:N films contain 
~19% Ti and ~10% N (for details including chemical binding and hydrogen contents in DLC films 
compare [58]). Hydrogen contents were found to be ~20–35 at. % of the diamond-like carbon coatings. 
Figure 3. (a) Surface topography (analyzed by scanning electron microscopy) and   
(b) growth structure (analyzed by high resolution transmission electron microscopy) of 
typical Ti:a-C:H:N films on PU substrate. 
 
The microtopography of the substrate materials is not altered by the coating (see SEM image in 
Figure 3a). The nanotopography on PU is roughened by stress-induced formation of ~5 nm high hills, 
separated 15 nm from one another (for details see [59]). The surface energy of the coatings on Si 
substrates in the same state as prepared for hemocompatible testing was measured based on sessile 
contact angle measurements with distilled water, diiodo methane and ethylene glycol 50% water (Carl 
Roth/Karlsruhe/Germany) and found rather similar range with polar contributions of 35–44 mN/m and 
disperse contribution of 5–12 mN/m. TiOx and TiN as well as Ti and a-C:H:N:Ti are on the lower level 
of this energy range (below 40 and 45 mN/m, respectively), while all other coating types are at the 
upper limit. Bacterial testing of the coatings with Eschierichia coli XL-blue (Agilent Technologies 
Inc./Loveland/CO/USA) revealed improved behavior of a-C:H, Ti, TiN and a-C:H:Ti compared to 
uncoated PU in both optical inspection of 12 h/37°C cultivated bacteria coated samples as well as 
bacterial counting in LB and Agar medium. 
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3.2. Platelet Function Testing 
3.2.1. Materials 
A fasting venous blood (4 × 4.5 mL) was drawn from the same male healthy donor (age 50 years) 
into sodium citrate tubes (0.5 mL, 0.105M concentration, BD Vacutainer Systems, Franklin Lakes, 
NY, USA) at one week intervals. A wide gauge needle (12 G) was used for blood sampling without 
any stasis to prevent platelet activation. For the same reason, the first sampling tube was rejected. 
Measurement of complete blood count was done using Sysmex K-1000 cell counter (Sysmex Co., 
Mundelein, IL, USA) calibrated each day. Aliquots of blood (0.4 mL) were stored at room temperature 
and were used for testing within 45 min. An additional blood aliquot was sampled at the time of the 
shear stress to investigate impact of static storage on platelet function. Another aliquot of blood was 
activated with adenosine diphosphate (ADP, 20 μM final concentration) for 5 min. The control 
samples were processed in parallel with each replicate of the shear stress experiment. These samples 
served baseline control for the static conditions and to test platelets capacity to activate. 
3.2.2. Cone-and-Plate(let) Analyzer Testing 
Testing of materials in the shear stress conditions was performed with a CPA device (Impact-R, 
DiaMed AG, Cressier (FR), Switzerland). The CPA is a commonly used instrument, validated for 
clinical use in the evaluation of thrombotic diseases and the effectiveness of anti-platelet drugs. It 
mimics vascular flow and—in the used modified setup—dynamic interaction between whole blood and 
biomaterial [60,61]. The rationales for using this test were: (1) lower requirements of donor blood to 
perform the test, (2) availability of commercial testing instrument, (3) accepted principle of a rotating 
cone and plate as a source of shear stress, as it is used in rheometers or viscometers [62]. 
As recommended by the manufacturer, 130 μL blood volume was used for each shear stress test and 
the aliquot of the blood was gently mixed for 60 seconds on the rotational wheel (10 revolutions per 
minute) to prevent sedimentation of blood cells before each of the replicates. Polystyrene (PS) being 
the standard disposable insert well of the Impact-R kit was used as reference for testing platelets and 
for test validation. For the biomaterial coating testing, these inserts were exchanged by the specimen 
(coated polyurethane), which were cut to disks of 19.5 mm diameter and 2 mm thickness, which fitted 
the insert well tightly (see Figure 4). 
Figure 4. Schematics of the cone-and-platelet analyzer (CPA) setup including the base 
plate, consisting of PU and biomaterial films deposited thereon. 
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The shear test was applied at a shear rate 1,800 s
−1 (720 revolutions per minute) for 300 seconds, 
using a disposable PTFE conical rotor. Following the shear test, the rotor was carefully removed and 
blood was immediately sampled from the well to the test tubes for flow cytometry staining. From the 
remaining blood (80 μL), plasma was separated by centrifugation at 2,000 g for 5 min and stored 
frozen in −70 °C for further analysis of thrombotic activity. 
3.2.3. Flow Cytometry for Platelet Analysis in Blood 
Two sets of tubes were prepared for each tested plate and for the static controls. Expression of 
platelet activation markers was ascertained using whole blood staining. In brief, 5 μL aliquots of blood 
were gently mixed with fluorochrome-conjugated monoclonal antibodies: 5 μL FITC-PAC-1, 5 μL  
PE-CD62P and 4 μL PerCP-CD61 (all from Becton Dickinson, USA) in phosphate buffered saline 
(PBS) containing 0.2% bovine serum albumin and 2 mM calcium chloride (final volume 35 μL). After 
10 min staining at room temperature, erythrocytes were lysed by addition of 0.5 mL lysing solution 
(FLS, Becton Dickinson, Franklin Lakes, NJ, USA) and platelets were centrifuged (1,000 g, 6 min) 
and resuspended in PBS buffer for further analysis by flow cytometry. Samples were analyzed using 
EPICS XL flow cytometer (Beckman Coulter Inc., Brea, CA, USA). Expression of platelet activation 
markers [42] was measured on CD61 gated objects using PAC-1 antibody for conformational change 
of glycoprotein IIb/IIIa, and using CD62P for P-selectin. Integrated fluorescence of the activation 
marker was calculated as a multiplication total of geometric mean fluorescence by percentage of 
marker-positive objects. Aggregates of platelets were analyzed after erythrocyte lysis by mixing 25 μL 
of blood with 0.4 mL FLS and subsequent fixation by the addition of 3.5 mL 1% paraformaldehyde in 
PBS. Cellular material was recovered by centrifugation (1,000 g, 7 min) and immunostained (25 μL 
aliquots) with 4 μL PerCP-CD14 and 5 μL FITC-CD61 or 5 μL FITC-CD61 alone for 30 min at room 
temperature. Samples were then washed in PBS, and analyzed by flow cytometry. The percentage of  
granulocyte-platelet aggregates (leukocytes stained with platelet marker CD61) was calculated using 
granulocyte forward/side scatter gate and additional monocyte CD14+ gate. The absolute number of 
platelets was calculated as the number of CD61 positive objects in reference to total granulocytes 
count. Small and big platelet aggregates were counted using forward/side scatter gates for CD61 
positive objects. All other chemicals were obtained from Sigma-Aldrich. 
3.2.4. Thromogenic Microparticle Activity Analysis 
Thrombogenic potential of blood plasma was measured using ZymuphenMP-activity ELISA kit 
(Hyphen Biomed, Eragny, France), according to the manufacturer’s instructions. This assay is based 
on trapping phospholipid-rich microparticles derived from cell membranes, using immobilized   
annexin V, followed by reconstitution of thrombin activity with calibrated clotting factors solution. 
Proteolytic activity of generated thrombin against the chromogenic substrate strictly correlates with 
concentration of microparticles present in blood plasma [63]. 
  J. Funct. Biomater. 2012, 3  293 
 
 
3.3. Statistics 
Statistical analysis was performed using ORIGIN Pro version 7.5 G and SPSS version 17.0 statistical 
packages. Data are presented as means ± SD (standard deviation) and ranges. Statistical significance 
was assumed for type-I error p < 0.05.  
4. Conclusions  
Magnetron sputtering as well as pulsed laser deposition was used to deposit titanium-based 
inorganic thin film materials (Ti, TiOx, TiN) as well as pure and doped DLC coatings of ~20 nm 
thickness on thermoplastic polyurethane surfaces. In-vitro testing the hemocompatibility under 
dynamic test conditions in an adapted device based on a cone-and-plate analyzer revealed for Ti, TiN 
and nitrogen doped DLC optimal anti-thrombotic behavior, being better as for the state-of-the-art 
polyurethane polymers (gold standard in clinics). This is due to the low tendency of platelet activation, 
aggregation and microparticle formation.  
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